Related Experiment Video
Updated: Jul 20, 2026
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
[Increased sensitivity to chemotherapeutic drug by RNAi targeting Hsp701A in HepG2 cells]
Qing Zhu1, Wang-gang Zhang, Li-feng Wang
1Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Aim:
To investigate the effects on chemotherapeutic sensitivity to the drugs of tumor cells induced by Hsp701A targeting siRNA expression vector.
Methods:
Specific small interference RNA (siRNA) targeting Hsp701A gene was generated and its eukaryotic expression vector was constructed and transfected into human HepG2 cells.Sensitivity to the chemotherapeutic drug of HepG2 cells transfected with the vector was detected by MTT colorimetry.
Results:
The eukaryotic expression vector of siRNA targeting Hsp701A was successfully constructed and transfected into human HepG2 cells. Sensitivity to the chemotherapeutic drug of HepG2 cells was increased after Hsp701A was knock down (P<0.05).
Conclusion:
Knockdown of Hsp701A gene by siRNA enhances sensitivity to chemotherapeutic drug in HepG2 cells.
Insights
Targeting Hsp701A with small interference RNA (siRNA) enhances cancer cell sensitivity to chemotherapy drugs. This study demonstrates that reducing Hsp701A levels can improve chemotherapeutic efficacy in HepG2 cells.
Area of Science:
- Molecular biology
- Cancer research
- Gene silencing
Context:
- Hepatocellular carcinoma (HCC) is a major global health concern.
- Chemotherapeutic resistance remains a significant challenge in HCC treatment.
- Heat shock protein 70 (Hsp70) is implicated in cancer progression and drug resistance.
Purpose:
- To investigate the impact of targeting Hsp701A using siRNA on the sensitivity of HepG2 cells to chemotherapeutic agents.
- To determine if reducing Hsp701A expression can overcome or mitigate chemotherapeutic resistance.
Summary:
- A small interference RNA (siRNA) targeting the Hsp701A gene was designed and its eukaryotic expression vector constructed.
- The vector was transfected into human HepG2 cells, a liver cancer cell line.
- MTT colorimetry assays revealed that knockdown of Hsp701A significantly increased HepG2 cell sensitivity to chemotherapeutic drugs (P<0.05).
Impact:
- This research provides a potential strategy for enhancing the effectiveness of chemotherapy in liver cancer.
- Targeting Hsp701A could represent a novel therapeutic approach to overcome drug resistance in HCC.
- The findings support the role of Hsp701A as a mediator of chemotherapeutic resistance in cancer cells.
